Do drugmakers need a reality check on prices?

02/11/2013 | Xconomy

Drugmakers have come under fire lately for six-figure annual pricing on some new drugs, and payers are beginning to push back. Instead of developing drugs for rare diseases as a way to stabilize profits, drugmakers should improve diagnostics and precision treatments, and should develop better treatments for diabetes, depression and other chronic diseases, says Alkermes CEO Richard Pops.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA